Oculis Holding AG
OCSHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeOculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The $1.37B market capitalization puts OCS squarely in small-cap range for its industry. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Market Cap
$1.37B
Beta
0.20
P/E (TTM)
—
P/E (Fwd)
-10.92
EPS (TTM)
$-2.15
EPS (Fwd)
$-2.08
ROE
-73.5%
ROA
-28.6%
Cash
$213.0M
Total Debt
$2.3M
Free CF
-$43.7M
52W Change
18.1%
Annual Financials
Cash vs Debt
With $213.0M in cash and $2.3M in debt, OCS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$43.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -73.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Oculis Holding AG typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OCS.